Products Fostemsavir was approved in the United States in 2020 in sustained-release (ER) tablet form (Rukobia). Fostemsavir is the first agent in this drug class. Structure and properties Fostemsavir (C25H26N7O8P, Mr = 583.5 g/mol) is a prodrug. It is present in the drug as fostemsavirtromethamine, which is biotransformed in the body to the active metabolite … Fostemsavir
Products Laninamivir has been approved in Japan as a powder inhaler since 2010 (Inavir). Structure and properties Laninamivir (C13H22N4O7, Mr = 346,340 g/mol) is present in the drug as laninamiviroctanoate, an octanoyl ester prodrug that is metabolized to the active ingredient laninamivir after application. Effects Laninamivir has antiviral properties against influenza viruses. The effects are … Laninamivir
